---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-391358"
form_type: "8-K"
ticker: "LBRX"
cik: "0001691082"
company_name: "LB PHARMACEUTICALS INC"
filed_at: "2026-09-15T12:05:07+00:00"
generated_at: "2026-09-15T12:10:34.152169+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# LB Pharmaceuticals appoints Susan Kozauer as Chief Medical Officer; $515k base, NOVA-2 readout H1 2027

## Summary
- Appointed Susan G. Kozauer, M.D. as CMO effective Sept 14, 2026; previously SVP at Centessa and VP at Intra-Cellular.
- Compensation: $515k annual base salary, 40% target bonus, $150k sign-on bonus, and 200,000-share option vesting over 4 years.
- CEO Heather Turner cites Kozauer's expertise as pivotal for Phase 3 NOVA-2 topline results in schizophrenia expected H1 2027.
- Kozauer led clinical development of CAPLYTA across schizophrenia, bipolar disorder, and MDD, resulting in multiple FDA approvals.

## SEC filing metadata
- accession: 0001193125-26-391358
- form_type: 8-K
- ticker: LBRX
- cik: 0001691082
- company_name: LB PHARMACEUTICALS INC
- filed_at: 2026-09-15T12:05:07+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/0001193125-26-391358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/d157620d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-391358
- JSON: https://secwatch.observer/filing/0001193125-26-391358.json
- Plain text: https://secwatch.observer/filing/0001193125-26-391358.txt

## Key facts
- Executive change
  Susan G. Kozauer was appointed as Chief Medical Officer at LB PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On September 15, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 14, 2026 (the “Start Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/0001193125-26-391358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.